Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'glycoprotein IIb' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1509 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Casterella, PJ; Kereiakes, DJ; Steinhubl, SR; Raymond, RE; Kottke-Marchant, K; Patel, K; Mueller, M; Rosenthal, M; Moliterno, DJ; Teirstein, PS
      The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    2. Lincoff, AM
      Anticoagulant and antiplatelet drugs

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    3. McCollam, PL; Lage, MJ; Bala, M
      A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    4. Paradiso-Hardy, FL; Madan, M; Radhakrishnan, S; Hurden, S; Cohen, EA
      Severe thrombocytopenia possibly related to readministration of eptifibatide

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    5. Simon, DI; Liu, CB; Ganz, P; Kirshenbaum, JM; Piana, RN; Rogers, C; Selwyn, AP; Popma, JJ
      A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    6. Martin, GS
      The hunting of the Src

      NATURE REVIEWS MOLECULAR CELL BIOLOGY
    7. Kiefel, V
      Platelet antibodies and diagnosis of immune-mediated thrombocytopenia

      INFUSION THERAPY AND TRANSFUSION MEDICINE-INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN
    8. Inwald, D; Davies, EG; Klein, N
      Demystified ... Adhesion molecule deficiencies

      JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY
    9. Akkerhuis, KM; van den Brand, MJBM; van der Zwaan, C; Peels, HOJ; Suryapranata, H; van der Wieken, LR; Stibbe, J; Hoffmann, J; Baardman, T; Deckers, JW; Simoons, ML
      Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

      HEART
    10. Vaisman, D; Ferguson, JJ
      Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    11. Nurden, P
      The anti-GPIIb-IIIa

      TRANSFUSION CLINIQUE ET BIOLOGIQUE
    12. Schmidt, AM; Stern, DM
      Chemokines on the rise - MCP-1 and restenosis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    13. Collett, JP; Montalescot, G; Lesty, C; Soria, J; Mishal, Z; Thoms, D; Soria, C
      Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    14. Abulencia, JP; Tien, N; McCarty, OJT; Plymire, D; Mousa, SA; Konstantopoulos, K
      Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    15. Casonato, A; Pontara, E; Vertolli, UP; Steffan, A; Durante, C; De Marco, L; Sartorello, F; Girolami, A
      Plasma and platelet von Willebrand factor abnormalities in patients with uremia: Lack of correlation with uremic bleeding

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    16. Santillan, MKO; Herring, J; Hoppensteadt, DA; Jeske, W; Herbert, JM; Fareed, J
      The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    17. Axelrod, DA; Wakefield, TW
      Future directions in antithrombotic therapy: Emphasis on venous thromboembolism

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    18. Burgess, JK
      Molecular mechanisms of drug-induced thrombocytopenia

      CURRENT OPINION IN HEMATOLOGY
    19. Spinler, SA; Hilleman, DE; Cheng, JWM; Howard, PA; Mauro, VF; Lopez, LM; Munger, MA; Gardner, SF; Nappi, JM
      New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines

      ANNALS OF PHARMACOTHERAPY
    20. Clutton, P; Folts, JD; Freedman, JE
      Pharmacological control of platelet function

      PHARMACOLOGICAL RESEARCH
    21. Bogousslavsky, J; Leclerc, JR
      Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke

      CEREBROVASCULAR DISEASES
    22. Easton, JD
      Future perspectives for optimizing oral antiplatelet therapy

      CEREBROVASCULAR DISEASES
    23. Knight, LC
      Radiolabeled peptide ligands for imaging thrombi and emboli

      NUCLEAR MEDICINE AND BIOLOGY
    24. Hantgan, RR; Rocco, M; Nagaswami, C; Weisel, JW
      Binding of a fibrinogen mimetic stabilizes integrin alpha IIb beta 3's open conformation

      PROTEIN SCIENCE
    25. Manaka, A; Sato, M; Aoki, M; Tanaka, M; Ikeda, T; Toda, Y; Yamane, Y; Nakaike, S
      2-acylimino-3H-thiazoline derivatives: A novel template for platelet GPIIb/IIIa receptor antagonists

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    26. Ervin, AL; Peerschke, EIB
      Platelet activation by sustained exposure to low-dose plasmin

      BLOOD COAGULATION & FIBRINOLYSIS
    27. Phillips, DR; Prasad, KSS; Manganello, J; Bao, M; Nannizzi-Alaimo, L
      Integrin tyrosine phosphorylation in platelet signaling

      CURRENT OPINION IN CELL BIOLOGY
    28. Holmes, MB; Kabbani, SS; Terrien, CM; Watkins, MW; Sobel, BE; Schneider, DJ
      Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab

      CORONARY ARTERY DISEASE
    29. Lucore, CL; Trask, RV; Mishkel, GJ; Rocha-Singh, KJ; Shelton, ME; Mikell, FL; Ligon, RW
      Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital

      CORONARY ARTERY DISEASE
    30. Kereiakes, DJ; Lorenz, T; Young, JJ; Kukielka, G; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR
      Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    31. Januzzi, JL; Chae, CU; Sabatine, MS; Jang, IK
      Elevation in serum troponin I predicts the benefit of tirofiban

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    32. Smith, BS; Gandhi, PJ
      Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins andglycoprotein IIb/IIIa receptor antagonists in renal failure

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    33. Zhang, YH; Chung, KH; Ryu, CK; Ko, MH; Lee, MK; Yun, YP
      Antiplatelet effect of 2-chloro-3-(4-acetophenyl)-amino-1,4-naphthoquinone(NQ301): A possible mechanism through inhibition of intracellular Ca2+ mobilization

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    34. Mine, S; Fujisaki, T; Suematsu, M; Tanaka, Y
      Activated platelets and endothelial cell interaction with neutrophils under flow conditions

      INTERNAL MEDICINE
    35. Zhang, YH; Chung, KH; Ryu, CK; Lee, YH; Kim, TJ; Song, YS; Hwang, KA; Yun, YP
      Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)amino-1,4-naphthoquinone (NQ304), an antithrombotic agent

      PHARMACOLOGY & TOXICOLOGY
    36. Nagahama, M; Nomura, S; Ozaki, Y; Yoshimura, C; Kagawa, H; Fukuhara, S
      Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus

      AUTOIMMUNITY
    37. Dai, W; Deubler, DA; Maxwell, TM; Zhu, XL; Cui, J; Rohr, LR; Stephenson, RA; Brothman, AR
      A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1

      GENOMICS
    38. Missy, K; Giuriato, S; Bodin, S; Plantavid, M; Payrastre, B
      Integrins and signal transduction: illustration with the alpha(IIb)beta(3)integrin in platelets

      M S-MEDECINE SCIENCES
    39. Lin, PH; Bush, RL; Tong, FC; Chaikof, E; Martin, LG; Lumsden, AB
      Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab

      JOURNAL OF VASCULAR SURGERY
    40. Anderson, KM; Califf, RM; Stone, GW; Neumann, FJ; Montalescot, G; Miller, DP; Ferguson, JJ; Willerson, JT; Weisman, HF; Topol, EJ
      Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    41. Neumann, FJ; Hochholzer, W; Pogatsa-Murray, G; Schomig, A; Gawaz, M
      Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    42. Lev, EI; Osende, JI; Richard, MF; Robbins, JA; Delfin, JA; Rodriguez, O; Sharma, SK; Jayasundera, T; Badimon, JJ; Marmur, JD
      Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    43. Salvati, F; Liani, M
      Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis

      INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
    44. Rossi, F; Rossi, E; Pareti, FI; Colli, S; Tremoli, E; Gallo, L
      In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion

      HAEMATOLOGICA
    45. Keh, D; Kurer, I; Dudenhausen, JW; Woltmann, W; Falke, KJ; Gerlach, H
      Response of neonatal platelets to nitric oxide in vitro

      INTENSIVE CARE MEDICINE
    46. Goldmann, BU; Hamm, CW
      Risk stratification in acute coronary syndrome

      HERZ
    47. Schror, K
      Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa antagonists

      HERZ
    48. Rendu, F; Brohard-Bohn, B; Pain, S; Bachelot-Loza, C; Auger, J
      Thiosulfinates inhibit platelet aggregation and microparticle shedding at a calpain-dependent step

      THROMBOSIS AND HAEMOSTASIS
    49. Topaz, O; Minisi, AJ; Bernardo, NL; McPherson, RA; Martin, E; Carr, SL; Carr, ME
      Alterations of platelet aggregation kinetics with ultraviolet laser emission: The "stunned platelet" phenomenon

      THROMBOSIS AND HAEMOSTASIS
    50. Derrick, JM; Shattil, SJ; Poncz, M; Gruppo, RA; Gartner, TK
      Distinct domains of alpha IIb beta 3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, an alphaIIb beta 3 interacting peptide

      THROMBOSIS AND HAEMOSTASIS
    51. Marques, JA; George, JK; Smith, IJ; Bhakta, V; Sheffield, WP
      A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro

      THROMBOSIS AND HAEMOSTASIS
    52. Fox, JEB
      Cytoskeletal proteins and platelet signaling

      THROMBOSIS AND HAEMOSTASIS
    53. Shattil, SJ; Leavitt, AD
      All in the family: Primary megakaryocytes for studies of platelet alpha IIb beta(3) signaling

      THROMBOSIS AND HAEMOSTASIS
    54. Woodside, DG; Liu, S; Ginsberg, MH
      Integrin activation

      THROMBOSIS AND HAEMOSTASIS
    55. Coller, BS
      Anti-GPIIb/IIIa drugs: Current strategies and future directions

      THROMBOSIS AND HAEMOSTASIS
    56. Sassoli, PM; Emmell, EL; Tam, SH; Trikha, M; Zhou, Z; Jordan, RE; Nakada, MT
      7E3 F(ab ')(2), an effective antagonist of rat alpha IIb beta 3 and alpha v beta 3, blocks in vivo thrombus formation and in vitro angiogenesis

      THROMBOSIS AND HAEMOSTASIS
    57. Bennett, JS; Mousa, S
      Platelet function inhibitors in the year 2000

      THROMBOSIS AND HAEMOSTASIS
    58. Bauer, M; Maschberger, P; Quek, L; Briddon, SJ; Dash, D; Weiss, M; Watson, SP; Siess, W
      Genetic and pharmacological analyses of involvement of Src-family, Syk andBtk tyrosine kinases in platelet shape change - Src-kinases mediate integrin alpha(IIb)beta(3) inside-out signaling during shape change

      THROMBOSIS AND HAEMOSTASIS
    59. Israels, SJ; McMillan-Ward, EM; Easton, J; Robertson, C; McNicol, A
      CD63 associates with the alpha(IIb)beta(3) integrin-CD9 complex on the surface of activated platelets

      THROMBOSIS AND HAEMOSTASIS
    60. Klinkhardt, U; Graff, J; Westrup, D; Kirchmaier, CM; Esslinger, HU; Breddin, HK; Harder, S
      Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    61. Graff, J; Andries, D; Elsner, M; Westrup, D; Bassus, S; Franz, N; Klinkhardt, U; Harder, S
      Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    62. Dopheide, SM; Yap, CL; Jackson, SP
      Dynamic aspects of platelet adhesion under flow

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    63. Boudreaux, MK; Lipscomb, DL
      Clinical, biochemical, and molecular aspects of Glanzmann's thrombastheniain humans and dogs

      VETERINARY PATHOLOGY
    64. Galeote, G; Pastor, AA; Carcamo, C; Sobrino, N; Calvo, L; Munoz, SG; Hussein, M; Fernandez-Chacon, JL; Sobrino, JA
      Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty

      REVISTA ESPANOLA DE CARDIOLOGIA
    65. Cokkinos, DV
      The treatment of coronary heart disease: An update - Part 4: Acute ischaemic coronary syndromes

      CURRENT MEDICAL RESEARCH AND OPINION
    66. Mathis, AS; Meswani, P; Spinler, SA
      Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines

      PHARMACOTHERAPY
    67. Spinler, SA; Inverso, SM
      Update on strategies to improve thrombolysis for acute myocardial infarction

      PHARMACOTHERAPY
    68. McKay, RG; Boden, WE
      Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials

      CURRENT OPINION IN CARDIOLOGY
    69. Chan, AW; Moliterno, DJ
      Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET

      CURRENT OPINION IN CARDIOLOGY
    70. Chang, CP; Chang, JC; Chang, HH; Tsai, WJ; Lo, SCJ
      Positional importance of Pro(53) adjacent to the Arg(49)-Gly(50)-Asp(51) sequence of rhodostomin in binding to integrin alpha IIb beta 3

      BIOCHEMICAL JOURNAL
    71. Gimeno, MJ; Gonzalez, J; Rodriguez, M; Corrales, C; Bellon, JM; Bujan, J
      Potential role of a new anti-beta 3 integrin antibody in the development of intimal hyperplasia after vascular surgery: an in vitro smooth muscle cell model

      HISTOLOGY AND HISTOPATHOLOGY
    72. Nicholson, NS; Abood, NA; Panzer-Knodle, SG; Frederick, LG; Page, JD; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB; Anders, RJ
      Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist

      MEDICINAL RESEARCH REVIEWS
    73. Christov, A; Kostuk, WJ; Jablonsky, G; Lucas, A
      Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty

      LASERS IN SURGERY AND MEDICINE
    74. Tcheng, JE; Strony, J; Lorenz, TJ; O'Shea, JC
      ESPRIT in context: pharmacology matters!

      EUROPEAN HEART JOURNAL
    75. Loubeyre, C; Lefevre, T; Louvard, Y; Dumas, P; Piechaud, JF; Lanore, JJ; Angellier, JF; Le Tarnec, JY; Karrillon, G; Margenet, A; Pouges, C; Morice, MC
      Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent

      EUROPEAN HEART JOURNAL
    76. Hallahan, DE; Geng, L; Cmelak, AJ; Chakravarthy, AB; Martin, W; Scarfone, C; Gonzalez, A
      Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature

      JOURNAL OF CONTROLLED RELEASE
    77. Zwart-van Rijkom, JEF; Klungel, OH; Leufkens, HGM; Broekmans, AW; Schrijver-van Velthoven, S; Umans, VA
      Costs and effects of combining stenting and abciximab (ReoPro (R)) in daily practice

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    78. Hantgan, RR; Stahle, M; Del Gaizo, V; Adams, M; Lasher, T; Jerome, WG; McKenzie, M; Lyles, DS
      alpha IIb's cytoplasmic domain is not required for ligand-induced clustering of integrin alpha IIb beta 3

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
    79. Suvire, FD; Rodriguez, AM; Mak, ML; Papp, JG; Enriz, RD
      Binding mechanism of RGD and its mimetics to receptor GPIIb/IIIa. A theoretical study

      JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
    80. Latham, C; Zhang, AJ; Nalbanti, A; Maner, S; Zickert, P; Blegen, H; Zetterberg, A
      Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas

      CANCER GENETICS AND CYTOGENETICS
    81. Fry, ETA
      Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: A combined role in coronary interventions?

      CLINICAL CARDIOLOGY
    82. Kang, WS; Chung, KH; Chung, JH; Lee, JY; Park, JB; Zhang, YH; Yoo, HS; Yun, YP
      Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    83. Amoroso, G; van Boven, AJ; van Veldhuisen, DJ; Tio, RA; Balje-Volkers, CP; Petronio, AS; van Oeveren, W
      Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients withcoronary artery disease

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    84. Truong, KM; Amankwa, K; Kucukarslan, S
      Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review

      CLINICAL THERAPEUTICS
    85. Qureshi, AI; Ali, Z; Suri, MFK; Kim, SH; Fessler, RD; Ringer, AJ; Guterman, LR; Hopkins, LN
      Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement

      NEUROSURGERY
    86. Akkerhuis, KM; Deckers, JW; Lincoff, AM; Tcheng, JE; Boersma, E; Anderson, K; Balog, C; Califf, RM; Topol, EJ; Simoons, ML
      Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    87. Pu, Q; Wiel, E; Corseaux, D; Bordet, R; Azrin, MA; Ezekowitz, MD; Lund, N; Jude, B; Vallet, B
      Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endotheliumin Escherichia coli endotoxin-induced shock

      CRITICAL CARE MEDICINE
    88. Parker, RI
      IIb/IIIa or not IIb/IIIa, that is adhesion

      CRITICAL CARE MEDICINE
    89. Bennett, JS
      Novel platelet inhibitors

      ANNUAL REVIEW OF MEDICINE
    90. Park, JW; Smolen, J
      Monoclonal antibody therapy

      ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    91. Wang, XF; Liu, FQ; Morris, SA; Carroll, RC
      Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization

      THROMBOSIS RESEARCH
    92. Sakariassen, KS; Hanson, SR; Cadroy, Y
      Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy

      THROMBOSIS RESEARCH
    93. Damiano, BP; Mitchell, JA; Giardino, E; Corcoran, T; Haertlein, BJ; de Garavilla, L; Kauffman, JA; Hoekstra, WJ; Maryanoff, BE; Andrade-Gordon, P
      Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist

      THROMBOSIS RESEARCH
    94. Cook, BC
      Reactivity of human platelets with immobilized fibrinogen is dictated by the chemical character of the surface

      THROMBOSIS RESEARCH
    95. Mousa, SA; Forsythe, MS
      Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography

      THROMBOSIS RESEARCH
    96. Erhardt, JA; Ohlstein, EH; Toomey, JR; Gabriel, MA; Willette, RN; Yue, TL; Barone, FC; Parsons, AA
      Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban

      THROMBOSIS RESEARCH
    97. Peter, K; Schwarz, M; Nordt, T; Bode, C
      Intrinsic activating properties of GP IIb/IIIa blockers

      THROMBOSIS RESEARCH
    98. Rossi, ML; Merlini, PA; Ardissino, D
      Percutaneous coronary revascularisation in women

      THROMBOSIS RESEARCH
    99. Verheugt, FWA
      GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction

      THROMBOSIS RESEARCH
    100. Darius, H
      Oral glycoprotein Ilb/IIa antagonists for unstable angina - Is there stilla chance for the oral substances?

      THROMBOSIS RESEARCH


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 18:52:10